Optimizing the Speed and Throughput of Therapeutic Antibody Development

Advances in target discovery and validation coupled with the ability to generate fully human antibodies against these targets is increasing the rate with which biotechnology companies can move promising new therapeutics into clinical development. To meet this challenge, new rapid development paradigms are needed to identify the best candidates and deliver quality therapeutics to patients. Regeneron's speed to clinic development strategy along with our approach for late-stage therapeutic development will be discussed in conjunction with an overview of the technologies used to facilitate these efforts.